Publications by authors named "Gerold Baake"

Claim this Profile
P
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Naiba Nabieva, Lothar Häberle, Sara Y Brucker, Wolfgang Janni, Bernhard Volz, Gerold Baake

Int J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.
Markus Wallwiener, Naiba Nabieva, Manuel Feisst, Tanja Fehm, Johann de Waal, Gerold Baake

BMC Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.
Marius Wunderle, Jutta Pretscher, Sara Y Brucker, Bernhard Volz, Arndt Hartmann, Gerold Baake

Breast Cancer Res Treat· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.
Carolin C Hack, Peter A Fasching, Tanja Fehm, Johann de Waal, Mahdi Rezai, Gerold Baake

Integr Cancer Ther· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.
Paul Gaß, Peter A Fasching, Tanja Fehm, Johann de Waal, Mahdi Rezai, Gerold Baake

Breast Care (Basel)· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Volker Heinemann, Ursula Vehling-Kaiser, Dirk Waldschmidt, Erika Kettner, Angela Märten, Gerold Baake

Gut· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis